Application 018885

Type
NDA
Sponsor
NOVARTIS

Application Products#

Product, Drug, Ingredient table
ProductDrugIngredientFormStrengthReference drugReference standard
001EMBOLEXDIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDEINJECTABLE;INJECTION0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5MLNoNo
002EMBOLEXDIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDEINJECTABLE;INJECTION0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7MLNoNo

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 2 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018885-001EMBOLEXDIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5MLINJECTABLE / INJECTION1984-11-30
N018885-002EMBOLEXDIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7MLINJECTABLE / INJECTION1984-11-30

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 3 of 3 · 90 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N018885-001EMBOLEX0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5MLINJECTABLE / INJECTION1984-11-303a93d1ddd44b…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N018885-002EMBOLEX0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7MLINJECTABLE / INJECTION1984-11-303a93d1ddd44b…
2022-10-28 04:53 UTC2022-10N018885-001EMBOLEX0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5MLINJECTABLE / INJECTION1984-11-30f41ea6bd6efb…
2022-10-28 04:53 UTC2022-10N018885-002EMBOLEX0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7MLINJECTABLE / INJECTION1984-11-30f41ea6bd6efb…
2022-09-29 23:25 UTC2022-09N018885-001EMBOLEX0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5MLINJECTABLE / INJECTION1984-11-30e64feba35796…
2022-09-29 23:25 UTC2022-09N018885-002EMBOLEX0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7MLINJECTABLE / INJECTION1984-11-30e64feba35796…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N018885-001EMBOLEX0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5MLINJECTABLE / INJECTION1984-11-30cb3db0bc1861…
2022-07-09 03:26 UTC · 3 captures of this ZIP2022-07N018885-002EMBOLEX0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7MLINJECTABLE / INJECTION1984-11-30cb3db0bc1861…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N018885-001EMBOLEX0.5MG/0.5ML;2,500 UNITS/0.5ML;5.33MG/0.5MLINJECTABLE / INJECTION1984-11-30a50c72e98297…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06N018885-002EMBOLEX0.5MG/0.7ML;5,000 UNITS/0.7ML;7.46MG/0.7MLINJECTABLE / INJECTION1984-11-30a50c72e98297…

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.